Targets

SHP2

4 articles

Medicinal ChemistryJournal of Medicinal Chemistry (ACS)

Covalent fragments reach lysines in the SHP2 allosteric latch site

  • Combines an electrophile-first covalent fragment screen with a ligand-first strategy to target lysines in the allosteric latch site of SHP2 phosphatase.
  • Computational and experimental analyses support the binding mode, and the work yields what the authors call the first potent, cell-active allosteric covalent inhibitors at this site.
  • It shows the latch site is covalently tractable, opening routes to new allosteric SHP2 chemotypes.
PointsBased on the abstract

Lysine-directed covalent chemistry is far rarer than cysteine, so a workflow that actually delivers cell-active hits on a lysine is the takeaway, more than SHP2 itself. My caveat is reactivity versus stability: lysine electrophiles can be hydrolytically fragile or reversible, so I'd want proteome-wide selectivity data before calling anything a probe.

Medicinal ChemistrychemRxiv

Can ternary-complex scoring rank close PROTAC linker analogues? A matched-pose test

  • Linker optimization in targeted protein degradation is still largely empirical.
  • The preprint asks whether current computational methods can rank close linker analogues before synthesis, the finest chemical differences yet tested.
  • It uses a matched-pose design on VHL-recruiting SHP2 degraders to isolate the effect of the linker.
  • This is a preprint, not yet peer reviewed; the snippet-level abstract available limits detail on the outcome.
PointsBased on the abstract

Linker tweaks are where PROTAC campaigns burn months of synthesis, so an honest test of whether scoring can separate near-identical analogues is more useful than another headline-grabbing benchmark. Matched poses remove the usual excuse that the method just got the geometry wrong. Even a negative answer helps: it tells us to keep building degradation and cooperativity assays rather than trusting a docked score.

Medicinal ChemistrychemRxiv

Chemists Report New Allosteric SHP2 Inhibitors Built on an Azaindole Scaffold

  • SHP2 is a cytosolic protein tyrosine phosphatase implicated in oncogenic RTK and immune checkpoint signaling, making it a closely watched cancer/immuno-oncology target.
  • Earlier allosteric SHP2 inhibitors have reached clinical trials but can face resistance mutations or PK limitations, motivating further chemotype exploration.
  • This preprint reports a new series of N-aryl-1H-azaindole-derived allosteric SHP2 inhibitors, shifting away from orthosteric (active-site) inhibition approaches.
PointsBased on the abstract

That shallow, conserved catalytic pocket is exactly why orthosteric SHP2 programs never went anywhere in my hands—no surprise this moves allosteric. But the irony's real: clinical allosteric inhibitors like TNO155 already picked up resistance mutations right in that allosteric tunnel, so a new chemotype needs to show it escapes those hotspots, not just re-occupy the same pocket with a different scaffold.

Medicinal ChemistryJournal of Medicinal Chemistry (ACS)

Lysine-Targeted Covalent Fragments Open a New Allosteric Route to Inhibit SHP2

  • Researchers built a combined screening pipeline pairing covalent fragment screening with a ligand-first design strategy to find chemical matter that reacts with lysine side chains rather than the more commonly targeted cysteines.
  • The work focuses on the allosteric "latch" region of SHP2 phosphatase, a regulatory site distinct from the enzyme's catalytic pocket and from previously drugged allosteric tunnel sites.
  • Computational modeling and experimental characterization were used together to guide fragment selection and to understand how covalent attachment at latch-site lysines affects the protein's conformational behavior.
  • The approach yielded inhibitors described as the first potent, cell-active covalent compounds acting through this latch site, indicating the pocket can support functional, drug-like engagement rather than only structural characterization.
  • The findings position lysine-directed covalent chemistry as a viable route for allosteric SHP2 modulation and provide a starting chemotype and site for further medicinal chemistry optimization.
PointsBased on the abstract

Lysine-directed covalency is the real bet here, more than the new pocket itself: warhead chemistry and selectivity triage are far less mature than for cysteine acrylamides, so the first thing I'd pull up is proteome-wide lysine reactivity data before trusting the cell activity. The latch site itself is also genuinely new — it sits apart from where SHP099/TNO155-type allosteric inhibitors already bind, so this isn't retreading crowded IP. Getting cell-active hits straight out of fragment screening is a strong signal for this pocket's shape or a hyperreactive lysine — but fragment-to-lead on Lys chemistry means slower SAR cycles than we're used to with Cys warheads. Real value: a fresh chemotype and site for a target whose allosteric space was starting to feel exhausted.